Third quarter revenues of $2.49 billion , up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.
99 , up 1.5% from 2023; and adjusted diluted EPS of $2.30 , up 3.
6% from 2023 Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion ; reported diluted EPS now expected to be between $7.
60 and $7.70 ; and adjusted diluted EPS expected to be between $8.85 and $8.
95 SECAUCUS, N.J. , Oct.
22, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX ), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2024. "We delivered a strong third quarter, with total revenue growth of 8.5%, including 4.
2% organic growth," said Jim Davis , Chairman, CEO and President. "Our performance was driven by new customer wins and expanded business with physicians and hospitals as well as recent acquisitions, including LifeLabs. We are now on track to complete eight acquisitions by year's end that meet our criteria for profitability, growth and returns.
" "We have increased our 2024 revenue guidance due to contributions from recent acquisitions and have maintained the midpoint of our adjusted EPS guidance despite the impact of Hurricane Milton in the fourth quarter," Mr. Davis continued. "Given the strength of our business and revenue from acquisitions, we are well positioned to drive accelerated revenue and earnings growth in 2025.
" Updated Guidance for Full Year 2024 .
